South Korea Fertility Drug Surgery Market Research Report By Underlying Cause (Male, Female), By Drugs (Clomiphene Citrate, Letrozole), By Procedures (Hysteroscopy, Laparoscopy, Robotic Laparoscopy) and By End User (Fertility Clinics) -Forecast to 2035
As per Market Research Future analysis, the South Korea fertility drug-surgery market size was estimated at 50.5 USD Million in 2024. The South Korea fertility drug-surgery market is projected to grow from 53.93 USD Million in 2025 to 104.0 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 6.7% during the forecast period 2025 - 2035
The South Korea fertility drug-surgery market is experiencing robust growth driven by increasing demand and technological advancements.
| 2024 Market Size | 50.5 (USD Million) |
| 2035 Market Size | 104.0 (USD Million) |
| CAGR (2025 - 2035) | 6.79% |
Merck KGaA (DE), Ferring Pharmaceuticals (CH), Bayer AG (DE), AbbVie Inc. (US), Eli Lilly and Company (US), SAGE Therapeutics (US), HRA Pharma (FR), Irvine Scientific (US)
Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry
The fertility drug-surgery market in South Korea is currently experiencing notable growth, driven by increasing awareness of reproductive health and advancements in medical technology. The rising prevalence of infertility issues among couples has led to a greater demand for effective treatment options. As a result, healthcare providers are expanding their offerings, incorporating both pharmaceutical and surgical interventions to address various fertility challenges. This trend is further supported by government initiatives aimed at promoting family planning and reproductive health services, which may enhance accessibility to these treatments. Moreover, the integration of innovative technologies, such as artificial intelligence and telemedicine, is transforming the landscape of the fertility drug-surgery market. These advancements facilitate personalized treatment plans and improve patient outcomes. The collaboration between healthcare professionals and technology developers appears to be fostering a more efficient and patient-centered approach to fertility care. As the market evolves, it is likely that stakeholders will continue to explore new avenues for enhancing service delivery and patient satisfaction, ultimately contributing to the overall growth of the sector.
The increasing awareness of reproductive health issues is driving a surge in demand for fertility treatments. Couples facing infertility challenges are actively seeking both drug and surgical options, leading to a more competitive landscape among healthcare providers.
Innovations in medical technology, including the use of artificial intelligence and telemedicine, are reshaping the fertility drug-surgery market. These advancements enable more personalized treatment plans and enhance patient engagement, potentially improving overall outcomes.
Government initiatives aimed at promoting reproductive health are playing a crucial role in the growth of the fertility drug-surgery market. By increasing accessibility to treatments and raising awareness, these programs may encourage more couples to seek assistance.
The rising incidence of infertility in South Korea serves as a significant driver for the fertility drug-surgery market. Factors such as delayed childbearing, lifestyle changes, and environmental influences contribute to this trend. Recent statistics indicate that around 1 in 6 couples in South Korea face infertility challenges, which has led to a growing need for effective treatment solutions. As the population grapples with these issues, the demand for fertility drugs and surgical procedures is expected to increase. This trend suggests that the fertility drug-surgery market will continue to expand, as healthcare providers respond to the needs of couples seeking assistance in their journey to parenthood.
A supportive regulatory environment plays a pivotal role in shaping the fertility drug-surgery market. In South Korea, government policies and regulations have been established to promote fertility treatments and ensure patient safety. Initiatives such as subsidies for fertility treatments and the establishment of guidelines for clinics contribute to a more accessible healthcare landscape. This regulatory support encourages investment in the fertility drug-surgery market, as healthcare providers are more likely to expand their services and adopt new technologies. Consequently, the fertility drug-surgery market is poised for growth, driven by a favorable regulatory framework that prioritizes reproductive health.
Cultural shifts towards family planning are influencing the fertility drug-surgery market in South Korea. As societal norms evolve, there is a growing acceptance of assisted reproductive technologies among younger generations. This shift is reflected in the increasing number of couples opting for fertility treatments, as they seek to balance career aspirations with family planning. The fertility drug-surgery market is likely to benefit from this trend, as more individuals view fertility treatments as viable options rather than stigmatized choices. This cultural transformation may lead to a sustained increase in demand for fertility drugs and surgical interventions, further propelling market growth.
The growing awareness of fertility issues among the population is a crucial driver for the fertility drug-surgery market. Educational campaigns and media coverage have highlighted the challenges faced by couples trying to conceive, leading to a surge in consultations with fertility specialists. In South Korea, approximately 15% of couples experience infertility, prompting many to seek medical assistance. This heightened awareness has resulted in increased demand for fertility drugs and surgical interventions, as individuals become more proactive in addressing their reproductive health. The fertility drug-surgery market is likely to benefit from this trend, as more people recognize the importance of early intervention and the available treatment options.
Advancements in reproductive technologies are transforming the landscape of the fertility drug-surgery market. Innovations such as in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and preimplantation genetic testing have enhanced the success rates of fertility treatments. In South Korea, the success rate of IVF has improved to approximately 40%, encouraging more couples to pursue these options. These technological advancements not only increase the effectiveness of treatments but also expand the range of services offered by fertility clinics. As a result, the fertility drug-surgery market is likely to experience growth as patients seek out the latest and most effective reproductive technologies.
In the South Korea fertility drug-surgery market, the distribution of market share between male and female segments reveals a substantial focus on female fertility treatments. The female segment dominates as the primary share holder, reflecting the higher demand for assisted reproductive technologies such as IVF and ovulation induction medications. Meanwhile, the male segment, while smaller in market share, exhibits a notable increase in its adoption of fertility solutions, driven by rising awareness of male infertility and advancements in treatment options.
Growth trends in this market segment are characterized by a significant increase in male fertility treatments as societal attitudes shift towards recognizing male infertility as a critical issue. Additionally, the increasing number of couples seeking fertility assistance has led to a rise in demand for male-related fertility drugs and surgical interventions. This trend points to a broader acceptance of male fertility issues, suggesting that the male segment may witness accelerated growth in the coming years as more men seek help and treatment, fostering a more balanced approach to fertility solutions.
Female (Dominant) vs. Male (Emerging)
The female segment in the South Korea fertility drug-surgery market is characterized by an established presence, driven by extensive offerings in reproductive technology and various fertility medications tailored to women's needs. As the dominant player, it benefits from a strong focus on comprehensive care, including hormonal treatments and surgical options like laparoscopy. On the other hand, the male segment, which is still considered emerging, is gaining momentum as awareness of male fertility issues rises. Innovative treatments such as sperm retrieval techniques and hormonal therapies have begun to carve out a niche, although they currently hold a smaller market share. This evolving scenario indicates that while the female sector remains predominant, the male segment is poised for rapid growth, attracting attention from both healthcare providers and patients.
In the South Korea fertility drug-surgery market, Clomiphene Citrate holds the largest market share among fertility drugs, attributed to its long-standing effectiveness and affordability. Its usage remains prevalent due to widespread awareness and acceptance among both healthcare providers and patients. Letrozole, while a newer entrant, is rapidly gaining traction due to its efficacy in triggering ovulation, particularly in patients who may not respond to Clomiphene, making it a considerable competitor in this segment.
The growth trends in this market are largely driven by increasing infertility rates coupled with rising awareness regarding fertility treatments. A shift towards more innovative therapies, such as Letrozole, highlights the market's adaptive nature. Additionally, supporting healthcare policies and advancements in reproductive health technologies provide favorable conditions for sustained growth in the sector.
Clomiphene Citrate: Dominant vs. Letrozole: Emerging
Clomiphene Citrate is recognized as the dominant drug within the South Korea fertility drug-surgery market due to its extensive clinical application and proven track record in treating ovulation disorders. It works by stimulating the release of hormones necessary for ovulation. In contrast, Letrozole, an emerging option, is becoming increasingly popular among specialists because of its efficacy and lower side effect profile. Letrozole functions as an aromatase inhibitor, promoting ovulation through a different mechanism. The growing preference for Letrozole among healthcare practitioners reflects a broader trend towards personalized treatment strategies aimed at maximizing patient outcomes.
Hysteroscopy currently leads the market share among procedures in the South Korea fertility drug-surgery market, appealing to a wide range of patients due to its minimally invasive nature. Following closely are Laparoscopy and Robotic Laparoscopy, which have been gaining traction owing to advancements in surgical technology that enhance precision and reduce recovery times.
Growth trends indicate a promising future for Laparoscopy, which has emerged as the fastest-growing procedure attributed to increasing awareness and acceptance of minimally invasive techniques among patients and healthcare professionals. Additionally, factors such as rising infertility rates and a growing focus on reproductive health are further driving demand in this segment, positioning it for significant expansion in the coming years.
Hysteroscopy (Dominant) vs. Laparoscopy (Emerging)
Hysteroscopy is established as the dominant procedure in the South Korea fertility drug-surgery market, primarily due to its effectiveness in diagnosing and treating conditions within the uterus. It enables doctors to perform various interventions with a high level of accuracy and minimal discomfort to patients. Conversely, Laparoscopy, which includes robotic-assisted options, is rapidly emerging as a favored choice for its ability to provide similar benefits while offering enhanced surgical visibility and versatility. As patient preferences shift towards quicker recovery times and less invasive options, Laparoscopy is well-positioned to capture a larger market share, supported by ongoing technological improvements and a growing emphasis on personalized patient care.
In the South Korea fertility drug-surgery market, the distribution of market share among end-user segments reveals that fertility clinics hold the largest share, significantly contributing to overall market dynamics. Hospitals, while currently smaller in comparison, are experiencing rapid growth, indicating a shift in patient preferences towards hospital-based fertility treatments. Clinical research institutes and other sectors play supportive roles, but they represent a smaller fraction of the market landscape.
Growth trends in this segment are driven by several factors, including increasing awareness of fertility issues, advancements in reproductive technologies, and a rise in government support for fertility treatments. The growing number of individuals seeking fertility solutions as societal norms evolve is also propelling hospitals into a competitive position, with clinics needing to innovate continuously to retain their leading status.
Fertility Clinics (Dominant) vs. Hospitals (Emerging)
Fertility clinics are the dominant players in the South Korea fertility drug-surgery market, offering specialized services that cater to couples seeking assistance with infertility. These clinics are often equipped with the latest reproductive technologies and provide tailored treatment plans, which enhances patient satisfaction and outcomes. In contrast, hospitals are emerging as significant competitors due to their integrated healthcare services, which appeal to patients who prefer a more comprehensive approach involving multiple medical disciplines. Hospitals are expanding their fertility programs, driven by increasing investments in reproductive health services, thus providing more accessible options for patients. This dynamic is leading to a robust competition between fertility clinics and hospitals as they each strive to meet the evolving needs of clients.
Get more detailed insights about South Korea Fertility Drug Surgery Market Request Free Sample
The fertility drug-surgery market in South Korea is characterized by a dynamic competitive landscape, driven by increasing demand for assisted reproductive technologies and a growing awareness of fertility issues. Key players such as Merck KGaA (DE), Ferring Pharmaceuticals (CH), and AbbVie Inc. (US) are strategically positioned to leverage innovation and partnerships to enhance their market presence. Merck KGaA (DE) focuses on expanding its product portfolio through research and development, while Ferring Pharmaceuticals (CH) emphasizes regional expansion and collaborations with local healthcare providers. AbbVie Inc. (US) is actively pursuing mergers and acquisitions to bolster its capabilities in reproductive health, thereby shaping a competitive environment that is increasingly collaborative and innovation-driven. In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The market structure appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies is significant, as they drive advancements in technology and treatment options, thereby influencing overall market dynamics. In October 2025, Merck KGaA (DE) announced a strategic partnership with a leading South Korean biotech firm to co-develop a novel fertility treatment. This collaboration is expected to enhance Merck's R&D capabilities and accelerate the introduction of innovative therapies tailored to the local market. Such partnerships are crucial in a landscape where localized solutions are increasingly valued by healthcare providers and patients alike. In September 2025, Ferring Pharmaceuticals (CH) launched a new fertility drug specifically designed for the South Korean market, which aims to address unique patient needs. This product introduction not only reflects Ferring's commitment to innovation but also highlights its strategy of tailoring offerings to meet regional demands, thereby strengthening its competitive position. In August 2025, AbbVie Inc. (US) completed the acquisition of a smaller fertility-focused company, enhancing its product pipeline and market reach. This acquisition is indicative of AbbVie's strategy to consolidate its position in the fertility sector, allowing it to offer a more comprehensive range of solutions to healthcare providers and patients. As of November 2025, current trends in the fertility drug-surgery market include a pronounced shift towards digitalization, sustainability, and the integration of artificial intelligence in treatment protocols. Strategic alliances are increasingly shaping the competitive landscape, as companies recognize the value of collaboration in driving innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements, innovative treatment options, and reliable supply chains, positioning companies to better meet the complex needs of patients and healthcare providers.
In recent months, the South Korea Fertility Drug Surgery Market has witnessed significant developments. Notable advancements in technology, coupled with increasing public awareness surrounding fertility issues, have intensified the demand for fertility treatments. Companies like Celltrion and Samsung Biologics have reported enhanced capacities to produce biologic drugs targeting fertility enhancement, reflecting a growing focus in this sector. Furthermore, the market is experiencing growth with the government facilitating access to fertility treatments, exemplified by policies aimed at subsidizing costs for assisted reproductive technologies.
In terms of mergers and acquisitions, in March 2023, Hanmi Pharmaceutical announced its acquisition of a local biotech firm specializing in fertility solutions, enhancing its portfolio in this growing market. Additionally, Genexine's partnerships with international firms translated to expanded R&D investments localized in South Korea, fostering innovation in fertility drugs. The South Korean Fertility Drug Surgery Market was valued significantly higher in 2022 compared to the previous year, driven by factors such as rising infertility rates and increasing societal acceptance of fertility treatments.
Given these dynamics, the market appears poised for healthy growth moving forward, particularly with ongoing advancements in drug formulations and surgical techniques aimed at improving patient outcomes.
The Fertility Drug Surgery Market is projected to grow at a 6.79% CAGR from 2025 to 2035, driven by technological advancements, increasing infertility rates, and enhanced healthcare access.
New opportunities lie in:
By 2035, the market is expected to achieve substantial growth, reflecting evolving consumer needs and technological innovations.
| MARKET SIZE 2024 | 50.5(USD Million) |
| MARKET SIZE 2025 | 53.93(USD Million) |
| MARKET SIZE 2035 | 104.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.79% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Merck KGaA (DE), Ferring Pharmaceuticals (CH), Bayer AG (DE), AbbVie Inc. (US), Eli Lilly and Company (US), SAGE Therapeutics (US), HRA Pharma (FR), Irvine Scientific (US) |
| Segments Covered | Underlying Cause, Drug, Procedures, End-User |
| Key Market Opportunities | Emerging technologies in reproductive health enhance treatment options in the fertility drug-surgery market. |
| Key Market Dynamics | Rising demand for advanced fertility treatments drives innovation and competition in the fertility drug-surgery market. |
| Countries Covered | South Korea |
The market valuation was $50.5 Million in 2024.
The projected valuation for 2035 is $104.0 Million.
The expected CAGR is 6.79% during the forecast period 2025 - 2035.
Key players include Merck KGaA, Ferring Pharmaceuticals, Bayer AG, AbbVie Inc., Eli Lilly and Company, SAGE Therapeutics, HRA Pharma, and Irvine Scientific.
The main segments include Underlying Cause, Drug, Procedures, and End-User.
The Drug segment had a valuation of $56.5 Million in 2024.
The Procedures segment is expected to grow from $47.5 Million in 2024 to a higher valuation by 2035.
The End-User segment was valued at $50.5 Million in 2024, with growth anticipated through 2035.
In the Underlying Cause segment, male treatments were valued at $62.5 Million and female treatments at $92.0 Million in 2024.
By 2035, the market is likely to see increased investments and advancements in fertility treatments, driven by the projected growth.
Kindly complete the form below to receive a free sample of this Report
“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”
“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”
“Thanks for sending the report it gives us a good global view of the Betaïne market.”
“Thank you, this will be very helpful for OQS.”
“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”
“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”
“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”
